Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367444 · ClinicalTrials.gov registry record · Phase 1
Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration
A Phase 1 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01367444 is a Phase 1 study that was terminated before completion, run by Sanofi. The registered enrollment target is 27 participants.
The verdict
NCT01367444, a Phase 1 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Primary Objective: To assess the safety and tolerability of ascending doses of SAR422459 in participants with Stargardt's Macular Degeneration (SMD). Secondary Objective: To evaluate for possible biological activity of SAR422459.
Interventions
- DRUG SAR422459
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-06-08 |
| Est. Completion | 2019-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01367444
The ClinicalTrials.gov registry entry for NCT01367444 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAR422459 is the first listed.
NCT01367444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01367444 about?
NCT01367444 is a clinical study titled "Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration". Primary Objective: To assess the safety and tolerability of ascending doses of SAR422459 in participants with Stargardt's Macular Degeneration (SMD). Secondary Objective: To evaluate for possible biological activity of SAR422459.
What is the current status of trial NCT01367444?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2011-06-08. Estimated completion is 2019-08-16.
What interventions are being tested in trial NCT01367444?
The interventions under investigation include: SAR422459 (DRUG).
Who is sponsoring clinical trial NCT01367444?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.